Cargando…
Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial
Histamine (HDC) inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer (NK) and T cells against oxidative damage. Thus, the addition of histamine may potentially improve the efficacy of interleukin-2 (IL-2). We have explored this potential me...
Autores principales: | Donskov, F, Hokland, M, Marcussen, N, Torp Madsen, H H, von der Maase, H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361121/ https://www.ncbi.nlm.nih.gov/pubmed/16434984 http://dx.doi.org/10.1038/sj.bjc.6602937 |
Ejemplares similares
-
In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma
por: Donskov, F, et al.
Publicado: (2004) -
Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival
por: Donskov, F, et al.
Publicado: (2002) -
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma
por: Donskov, F, et al.
Publicado: (2005) -
Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma
por: Jeppesen, A N, et al.
Publicado: (2010) -
Supreme Emergencies Without the Bad Guys
por: Sandin, Per
Publicado: (2008)